1999-2019: 20 Years of Advocacy in Action MSF’s Access Campaign marks 20 years of work to secure access to affordable medicines, diagnostics and vaccines, and to stimulate medical innovation that answers public health needs JOIN US!
Infographics: Hepatitis C Filter by - Any -CampaignEventsFact sheetFeature storyInfographicInterviewIssue briefLetterNewsletterOpinion articlePhoto storyPress releaseReportReport seriesResearch articleSpeechSpotlightStatementStoryTechnical briefThe issuesTopic overviewVideo Technical brief Technical brief | 11 March 2019 Hepatitis C MSF Access Campaign analysis of the MPP Licence Agreement with AbbVie for glecaprevir/pibrentasvir (G/P) Technical brief | 07 March 2019 Hepatitis C MPP licence agreement with AbbVie for glecaprevir/pibrentasvir Letter Letter | 11 February 2019 Hepatitis C Malaysia Malaysia’s compulsory license for sofosbuvir is a positive step for public health and innovation Press release Press release | 05 December 2018 Hepatitis C Europe Health groups appeal European Patent Office decision to uphold Gilead’s patent on hepatitis C drug 3 min Load More Tags Hepatitis C
Technical brief Technical brief | 11 March 2019 Hepatitis C MSF Access Campaign analysis of the MPP Licence Agreement with AbbVie for glecaprevir/pibrentasvir (G/P)
Technical brief | 07 March 2019 Hepatitis C MPP licence agreement with AbbVie for glecaprevir/pibrentasvir
Letter Letter | 11 February 2019 Hepatitis C Malaysia Malaysia’s compulsory license for sofosbuvir is a positive step for public health and innovation
Press release Press release | 05 December 2018 Hepatitis C Europe Health groups appeal European Patent Office decision to uphold Gilead’s patent on hepatitis C drug 3 min
